Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).
Tabernero, J Shitara, K Dvorkin, M Mansoor, Was Arkenau, H Prokharau, A Alsina, M Ghidini, M Faustino, C Gorbunova, V
Tabernero, J
Shitara, K
Dvorkin, M
Mansoor, Was
Arkenau, H
Prokharau, A
Alsina, M
Ghidini, M
Faustino, C
Gorbunova, V
Citations
Altmetric:
Abstract
Description
Date
2018-06
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). 2018, 29(suppl_5): Ann Oncol